SLC5A2 and chronic kidney disease: Our current study suggests when paired with a relatively normal salt diet, SGLT2 inhibitors do not elicit a chronic RAS response, even in the absence of RAS inhibitors, similar to findings in healthy subjects (Isshiki et al., 2020) and experimental studies in a rat model of CKD (Li et al., 2018).